Literature DB >> 2119791

Increased serum levels of soluble IL-2 receptor, CD30 and CD8 molecules, and gamma-interferon in angioimmunoblastic lymphadenopathy: possible pathogenetic role of immunoactivation mechanisms.

G Pizzolo1, H Stein, O Josimovic-Alasevic, F Vinante, R Zanotti, M Chilosi, A C Feller, T Diamantstein.   

Abstract

Abnormal immunoreaction associated with increased cell activation phenomena might play a role in the pathogenetic events leading to the development of angioimmunoblastic lymphadenopathy (AILD). In the present study we investigated the serum levels of some soluble molecules related to cell activation in 24 patients with AILD at presentation. In particular, we measured by immunoenzymatic or immunoradiometric techniques the levels of the Tac peptide (sIL-2R), soluble CD30 (sCD30) and CD8 (sCD8) antigens, and gamma-IFN (gIFN). The results show that all the above molecules are increased as compared to normal controls, with a different pattern of increase for the different molecules. The sIL-2R levels were very high in all cases with no overlap between AILD and control samples (mean 6315 +/- 3374 U/ml, controls 271 +/- 112 U/ml, P less than 0.001). Very high values of the sCD30 antigen (722 +/- 895 U/ml) were detected in all cases but five, as opposed to the lack of detectable levels in controls. A significant increase of sCD8 (978 +/- 646 U/ml, controls 334 +/- 95 U/ml, P less than 0.01) and gIFN (329 +/- 236 U/ml, controls 97 +/- 43 U/ml, P less than 0.01) was also observed with some overlap between AILD samples and controls. The above findings further support the view that a condition of abnormally enhanced cell activation is likely to play a central role in the pathogenetic events leading to the composite clinicopathological picture of AILD.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2119791     DOI: 10.1111/j.1365-2141.1990.tb07786.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

1.  Serum soluble CD4, CD8 and IL-2R levels in adult acute myeloid leukemia in remission.

Authors:  Y Iizuka; M Aiso; T Ohshima; S Sawada; T Horie
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

2.  Uncommon late relapse of angioimmunoblastic T-cell lymphoma after 16-year remission period.

Authors:  Edit Páyer; Zsófia Miltényi; Zsófia Simon; Lajos Szabados; Katalin Hegyi; Gábor Méhes; Arpád Illés
Journal:  Pathol Oncol Res       Date:  2011-11-30       Impact factor: 3.201

3.  CD30 antigen in embryonal carcinoma and embryogenesis and release of the soluble molecule.

Authors:  U Latza; H D Foss; H Dürkop; F Eitelbach; K P Dieckmann; V Loy; M Unger; G Pizzolo; H Stein
Journal:  Am J Pathol       Date:  1995-02       Impact factor: 4.307

4.  Lymphocyte activation in patients with acute myeloid leukaemia. Evidence for the presence of myeloblast antigen?

Authors:  S H Lim; C P Worman; A H Goldstone
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

Review 5.  Hodgkin's lymphoma and CD30 signal transduction.

Authors:  Ryouichi Horie; Masaaki Higashihara; Toshiki Watanabe
Journal:  Int J Hematol       Date:  2003-01       Impact factor: 2.490

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.